Wesana Health Holdings Inc. (WSNAF)
| Market Cap | 251.48K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.13M |
| Shares Out | n/a |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,250 |
| Average Volume | 9,553 |
| Open | 0.0107 |
| Previous Close | 0.0290 |
| Day's Range | 0.0107 - 0.0107 |
| 52-Week Range | 0.0025 - 0.1500 |
| Beta | -0.82 |
| RSI | 40.66 |
| Earnings Date | May 16, 2025 |
About Wesana Health Holdings
Wesana Health Holdings Inc. does not have significant operations. Previously, it was developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological, and mental health ailments caused by trauma. The company is headquartered in Chicago, Illinois. [Read more]
Financial Performance
Financial StatementsNews
Wesana Health Announces Change to The Board of Directors
Chicago, Illinois and Toronto, Ontario--(Newsfile Corp. - January 24, 2025) - Wesana Health Holdings Inc. (CSE: WESA.X) (OTC Pink: WSNAF) (the "Company") is pleased to announce the appointment of Mark...
Wesana Health Announces Restructuring of Promissory Note Receivable
Chicago, Illinois and Toronto, Ontario--(Newsfile Corp. - November 28, 2023) - Wesana Health Holdings Inc. (CSE: WESA.X) (OTCQB: WSNAF) (the "Company"), announced the execution of a Confidential Settl...
CSE Bulletin: Symbol Change - Inactive Designation - Wesana Health Holdings Inc. (WESA)
Toronto, Ontario--(Newsfile Corp. - Le 11 juillet/July 2023) - The Exchange has determined that Wesana Health Holdings Inc. (the “Issuer”) has not met the continued listing requirements as set out in ...
Wesana Health Announces Closing of Previously Announced SANA-013 Asset Sale
CHICAGO and TORONTO, July 05, 2023 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE:WESA; OTCQB:WSNAF), today announced the successful closing of the sale by Wesana Hea...
Wesana Health Announces Voting Results of AGSM
CHICAGO and TORONTO, June 09, 2023 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), today announced that all matters put forward at the Company's ...
Wesana Health Announces Sale of SANA-13 Assets to Lucy Scientific Discovery
CHICAGO and TORONTO, March 21, 2023 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company, today announced that the...
Wesana Health Announces Receipt of Short-Term Loan
CHICAGO and TORONTO, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company, today announced that Wesa...
Wesana Announces Sale of Clinic Management Services Organization
CHICAGO and TORONTO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the...
Wesana Announces Second Quarter 2022 Financial Results
CHICAGO and TORONTO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the ...
Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies
His talk will kick-off the daylong biotechnology conference on cutting-edge therapies His talk will kick-off the daylong biotechnology conference on cutting-edge therapies
Wesana Announces First Quarter 2022 Financial Results
CHICAGO and TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the n...
Wesana Health Outlines Accelerated Drug Development Pathway
CHICAGO and TORONTO, May 10, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the n...
Wesana Announces Singular Focus on Drug Development Prompting a Strategic Review of its Clinics and Other Care Delivery Assets
CHICAGO and TORONTO, May 05, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the n...
Wesana Health Reports Q4 2021 Financial Results and Provides Subsequent Period Highlights
CHICAGO and TORONTO, May 02, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the n...
Wesana Is Exploring Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder
Concurrently, the Company is launching a non-brokered private placement
Wesana Health CEO Daniel Carcillo to Speak at Several Leading Investor and Industry Events
CHICAGO and TORONTO, March 29, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the...
Wesana Health Announces New Findings Indicating Psylocibin Potentiates Impact of an Anti-Depressant
CHICAGO and TORONTO, March 22, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the...
Wesana Health Announces Positive Feedback From Pre-IND Meeting With FDA on SANA-013
Pre-IND Meeting is a Significant Milestone in the Clinical Development of SANA-013, Defining the Pathway to Initiate in-Human Clinical Trials in Q4 2022 Pre-IND Meeting is a Significant Milestone in t...
Wesana Provides Updates on Build-out of Third Clinic
Naperville clinic to open Spring 2022 Naperville clinic to open Spring 2022
Wesana Health Appoints Meghna A. Gaeta as Chief Marketing Officer
CHICAGO and TORONTO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the...
Wesana Health Announces Positive Findings From Animal Study on Novel Depression Treatment Protocol Combining Psilocybin and Cannabidiol
CHICAGO and TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the ...
Wesana Health Provides Strategic and Operational Updates
CHICAGO and TORONTO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data driven life sciences company focused on developing the...
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines. Field Trip Receives Notice Of Patent Allowance For Proprietar...
MAPS and Wesana Health Resume Negotiations
Analysis indicates viability of research pathway for MDMA-assisted therapy to treat symptoms associated with traumatic brain injury Analysis indicates viability of research pathway for MDMA-assisted t...
Wesana Completes Filing of PCT Patents for Novel Drug Protocols
CHICAGO and TORONTO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company, is pleased to announce t...